Historically, HER2 positive breast cancers have been associated with poor prognosis, although the development of targeted anti-HER2 therapies (e.g., trastuzumab) in the last decade has significantly improved overall survival [5]. The gene discussed is ERBB2; the disease is breast carcinoma.